Trials / Unknown
UnknownNCT03771846
HAIC Versus Systemic Chemotherapy for Unresectable ICC
Hepatic Arterial Infusion Chemotherapy of Irinotecan, Oxaliplatin, 5-Fluorouracil and Leucovorin Versus Systemic Chemotherapy of Gemcitabine and Oxaliplatin for Unresectable Intrahepatic Cholangiocarcinoma
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 188 (estimated)
- Sponsor
- Shi Ming · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) of irinotecan, oxaliplatin, 5-fluorouracil and leucovorin compared systemic chemotherapy of gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | irinotecan, oxaliplatin , fluorouracil, and leucovorin | administration of irinotecan, oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries |
| DRUG | gemcitabine and oxaliplatin | administration of gemcitabine and oxaliplatin via vein |
Timeline
- Start date
- 2018-08-01
- Primary completion
- 2022-08-01
- Completion
- 2022-08-01
- First posted
- 2018-12-11
- Last updated
- 2019-12-05
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03771846. Inclusion in this directory is not an endorsement.